Immunological modulation of dermal fibroblasts in scleroderma
- PMID: 2488871
Immunological modulation of dermal fibroblasts in scleroderma
Abstract
Scleroderma can be considered as a model to study the mechanism of fibrosis. Lymphocytes and monocytes/macrophages are recruited during the inflammatory process associated with this disorder. These activated blood cells release a series of factors--lymphokines and monokines--which in turn recruit more fibroblasts, possibly stimulate their proliferation, and regulate their synthesis of collagen and glycosaminoglycans. These factors represent both positive and negative modulators for these processes. It may be the absence of an inhibitory factor(s) and/or presence of other stimulator(s) which allow the fibroblast to synthesize collagen in an uncontrolled manner, leading to the increased accumulation of this protein in the dermis. Although there is an increase in collagen accumulation in vitro, the ratio of type I/type III collagen remains unaltered. It has been suggested that an increase in T-helper cells could explain the production of collagen stimulatory lymphokines. Collagen production may also be regulated by a feedback mechanism involving the amino and carboxyl propeptides of procollagen. In scleroderma this mechanism may be altered by the lymphokine/monokine factor(s) which affect collagen synthesis. Fibrosis probably is not the primary event in scleroderma but represents the final or terminal stage of the disease. Future research on the interactions which take place between the cells of the immune system and fibroblasts may clarify the mechanism of fibrosis in scleroderma and other disorders.
Similar articles
-
Connective tissue metabolism including cytokines in scleroderma.Curr Opin Rheumatol. 1992 Dec;4(6):869-77. Curr Opin Rheumatol. 1992. PMID: 1457283 Review.
-
Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts.Arthritis Rheum. 1998 Nov;41(11):2039-47. doi: 10.1002/1529-0131(199811)41:11<2039::AID-ART20>3.0.CO;2-1. Arthritis Rheum. 1998. PMID: 9811060
-
Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells.Arthritis Rheum. 2006 Jan;54(1):214-25. doi: 10.1002/art.21497. Arthritis Rheum. 2006. PMID: 16385517
-
Products of activated mononuclear cells modulate accumulation of collagen by normal dermal and scleroderma fibroblasts in culture.J Lab Clin Med. 1984 Sep;104(3):355-69. J Lab Clin Med. 1984. PMID: 6088655
-
Activation of dermal connective tissue in scleroderma.Ann Med. 1993 Dec;25(6):511-8. Ann Med. 1993. PMID: 8292298 Review.
Cited by
-
A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways.Front Immunol. 2025 Apr 16;16:1551911. doi: 10.3389/fimmu.2025.1551911. eCollection 2025. Front Immunol. 2025. PMID: 40308583 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical